Policy & Regulation
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
9 January 2026 - Swedish biopharmaceutical company Camurus (STO: CAMX), which develops long-acting medicines for severe and chronic diseases, said on Friday that the US Food and Drug Administration (F...
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
9 January 2026 - Acousia Therapeutics GmbH, a clinical-stage biotechnology company based in Germany, announced on Thursday that it has completed patient enrolment in its Phase 2 PROHEAR clinical study...
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
9 January 2026 - Clinical-stage life sciences company ZYUS Life Sciences Corporation (TSXV:ZYUS) on Thursday reported favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatmen...
Antin to acquire clinical trial equipment provider Emsere
8 January 2026 - Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.Emse...
Foresee licenses global rights to MMP-12 inhibitor programmes to Primevera
8 January 2026 - Taiwan-based biopharmaceutical company Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576) said on Thursday that it has granted exclusive global rights to its MMP-12 inhibitor programmes t...
Arbele's ARB1002 receives US FDA Orphan Drug Designation
8 January 2026 - Arbele, a Hong Kong-based biotechnology company focused on developing innovative targeted cancer therapies, announced on Wednesday that it has received Orphan Drug Designation (ODD) f...